OncoMatch/Clinical Trials/NCT05101213

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

Is NCT05101213 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Virus-specific Cytotoxic T-lymphocytes for adenovirus infection.

Phase 1RecruitingM.D. Anderson Cancer CenterNCT05101213Data as of May 2026

Treatment: Virus-specific Cytotoxic T-lymphocytes — This phase I trial tests the feasibility and safety of genetically modified cytotoxic T-lymphocytes in controlling infections caused by adenovirus (ADV), BK virus (BKV), cytomegalovirus (CMV), JC virus (JCV), or COVID-19 in immunocompromised patients with cancer. Viral infections are a leading cause of morbidity and mortality after hematopoietic stem cell transplantation, and therapeutic options for these infections are often complicated by associated toxicities. Genetically modified cytotoxic T-lymphocytes (CTLs) are designed to kill a specific virus that can cause infections. Depending on which virus a patient is infected with (ADV, BKV, CMV, JCV, or COVID-19), the CTLs will be designed to specifically attack that virus. Giving genetically modified CTLs may help to control the infection.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Non-Hodgkin Lymphoma

Multiple Myeloma

Myelodysplastic Syndrome

Chronic Lymphocytic Leukemia

Tumor Agnostic

Prior therapy

Must have received: allogeneic hematopoietic stem cell transplant

For BKV, ADV or CMV infections: Prior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using bone marrow, peripheral blood stem cells or single or double umbilical cord blood.

Cannot have received: anti-thymocyte globulin

Patients who have received anti-thymocyte globulin (ATG) within 14 days

Cannot have received: donor lymphocyte infusion

have received donor lymphocyte infusion (DLI) ... within 28 days of enrollment

Cannot have received: campath

have received ... campath within 28 days of enrollment

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

M D Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify